|Bid||69.54 x 900|
|Ask||899.99 x 1000|
|Day's Range||73.00 - 77.23|
|52 Week Range||19.31 - 99.50|
|Beta (3Y Monthly)||2.84|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||131.57|
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced the appointment of Geoffrey A. Block, M.D., as Vice President, Nephrology. Dr. Block, a world-renowned nephrologist, joins Reata with over 20 years of experience conducting clinical research and treating patients with chronic kidney disease (CKD). Dr. Block served as the Director of Clinical Research in the Denver Nephrology Research Division at Colorado Kidney Care/Denver Nephrologists. Dr. Block has participated in multiple clinical studies of bardoxolone methyl (bardoxolone), Reata’s lead clinical candidate, and recently presented results from both the Phase 2 CARDINAL and Phase 2 PHOENIX trials of bardoxolone in rare forms of CKD at the American Society of Nephrology Kidney Week 2018.
In light of the recent volatility in the credit markets, it is more critical than ever to make sure small developmental firms have enough of a cash runway in place to avoid a financing crunch in the foreseeable future. The biotech sector seems ripe for some bargain hunting after small biotechs fell nearly 20% in 2019 after a sharp decline in the fourth quarter. Iovance's lead product candidate is an adoptive cell therapy using TIL (Tumor Infiltrating Lymphocytes) technology that is being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent/metastatic or persistent cervical cancer and locally advanced or metastatic non-small cell lung cancer.
Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that it has completed a successful end-of-Phase 2 meeting with the United States Food and Drug Administration (FDA) regarding the design of a Phase 3 clinical trial of bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD). The trial, named FALCON, will be an international, double-blind, placebo-controlled, parallel group, Phase 3 trial. The Company plans to enroll approximately 300 ADPKD patients randomized 1:1 to oral, once-daily bardoxolone or placebo. The trial will include ADPKD patients from 18 to 70 years old with an estimated glomerular filtration rate (eGFR) between 30 to 90 mL/min/1.73 m2. The primary efficacy endpoint is the change from baseline in eGFR compared to placebo after 48 weeks of treatment followed by a 4-week drug withdrawal period, the retained eGFR benefit.
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -30.49% and -45.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
IRVING, Texas, Nov. 07, 2018 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today provided an update on the Company's product.
Investors need to pay close attention to Reata Pharmaceuticals (RETA) stock based on the movements in the options market lately.
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellularRead More...
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -40.54% and -16.89%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
These stocks jumped much higher over the last few days. But should investors jump on the bandwagon?
CORAL GABLES, FL / ACCESSWIRE / July 24, 2018 / The Nasdaq Biotechnology Index (IBB) just made a new 52-week high today and most likely an all-time high may not be out of the question either. As most of the market shutters about the trade wars, biotech stocks are more insulated from the biggest concern about tariffs compared to most industries. Biotech companies like GT Biopharma, Inc. (GTBP), Reata Pharmaceuticals (NASDAQ: RETA) and Biogen (NASDAQ: BIIB) have all released news within the last 10 days that has sparked much more interest in the market for these stocks.